<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708849</url>
  </required_header>
  <id_info>
    <org_study_id>1501015203</org_study_id>
    <nct_id>NCT02708849</nct_id>
  </id_info>
  <brief_title>The Sustained Effects of Ketamine</brief_title>
  <official_title>The Sustained Effects of Ketamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize the effects of a single, sub-anesthetic dose of
      ketamine in rs-fMRI in healthy subjects. Post-ketamine rs-fMRI data will demonstrate a
      pattern of increased global brain connectivity (GBC) in fronto-temporal cortex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, healthy participants will be randomized into one of two parallel groups: (a)
      open-label ketamine and active lamotrigine, or (b) open-label ketamine with a matched-placebo
      control (i.e., sugar pill). All participants will complete a baseline rs-fMRI approximately
      1-week prior to the ketamine infusion and a follow-up rs-fMRI 24-hours post-infusion. The
      subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over
      approximately 60 minutes) will be administered via intravenous infusion to occur during the
      MRS scan. Participants will be administered lamotrigine (300 mg oral dose) or the
      matched-placebo control about 2-hours prior to the start of the infusion.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Ketamine Rs-fMRI Data</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hours post infusion fMRI data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Brain Connectivity</measure>
    <time_frame>24 hours</time_frame>
    <description>Participants will be randomized into one of two parallel groups—ketamine+lamotrigine or ketamine+placebo—and will complete pre- and post-ketamine rs-fMRI.
The hypothesis is that post-ketamine rs-fMRI data will demonstrate a pattern of increased global brain connectivity (GBC) in fronto-temporal cortex.
Insufficient number of participants for data collection.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Mental Disorders</condition>
  <arm_group>
    <arm_group_label>Ketamine plus lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion</description>
    <arm_group_label>Ketamine plus lamotrigine</arm_group_label>
    <arm_group_label>ketamine plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine</description>
    <arm_group_label>Ketamine plus lamotrigine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral dose placebo</description>
    <arm_group_label>ketamine plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 21-65 years. Females will be included if they are
             not pregnant and agreed to utilize a barrier method contraceptive (e.g., condom or
             diaphragm with spermicide) tubal ligation, abstinence, or partner with vasectomy) or
             if post-menopausal for at least 1 year, or surgically sterile.

          -  Able to provide written informed consent according to Yale HIC guidelines.

          -  Agree to refrain from elective surgeries (including dental) for a 2-week period
             following study drug.

          -  Able to read and write English as a primary language.

        Exclusion Criteria:

          -  Personal history of mood, anxiety, or psychotic axis I DSM-IV disorders confirmed
             after comprehensive psychiatric evaluation.

          -  Any history of serious medical or neurological illness.

          -  Any signs of major medical or neurological illness on examination or as a result of
             ECG screening or laboratory studies.

          -  A first-degree family member with history of schizophrenia.

          -  Lifetime history of psychoactive substance or alcohol dependence or substance or
             alcohol abuse (other than nicotine or caffeine abuse), or drinking more that 5
             drinks/week during the last year.

          -  Abnormality on physical examination. A subject with a clinical abnormality may be
             included only if the study physician considers the abnormality will not introduce
             additional risk factors and will not interfere with the study procedure (e.g.
             uncontrolled hypertension, hyperthyroidism, or hypothyroidism will be excluded).

          -  A positive pre-study (screening) urine drug screen or, at the study physician's
             discretion on any drug screens given before the scans.

          -  Pregnant or lactating women or a positive urine pregnancy test for women of
             child-bearing potential at screening or prior to any imaging day.

          -  Positive HIV or Hepatitis B/C tests. This test will take place at the screening visit.
             Subjects will be invited back either for their next study visit or for a HIV/Hep
             debriefing session. A study clinician will inform them in person of the results. They
             will be given access to counselling and advised of the appropriate next steps.

          -  Has received either prescribed or over-the-counter (OTC) centrally active medicine or
             herbal supplements within the week prior to the MRI scan. Subjects who have taken OTC
             medication or herbal supplements may still be entered into the study, if, in the
             opinion of the principal/co-investigator, the medication received will not interfere
             with the study procedures or compromise safety.

          -  Any history indicating learning disability, mental retardation, or attention deficit
             disorder.

          -  Known sensitivity to ketamine.

          -  Known sensitivity to lamotrigine.

          -  Body weight of 250 pounds or greater.

          -  History of claustrophobia.

          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal
             foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening
             questionnaire.

          -  Donation of blood in excess of 500 mL within 56 days prior to dosing.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Resting blood pressure lower than 90/60 or higher than 150/90, or resting heart rate
             lower than 45/min or higher than 100/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadi Abdallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation, Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <results_first_submitted>April 27, 2020</results_first_submitted>
  <results_first_submitted_qc>June 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2020</results_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02708849/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine Plus Lamotrigine</title>
          <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Lamotrigine: lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine</description>
        </group>
        <group group_id="P2">
          <title>Ketamine Plus Placebo</title>
          <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Placebo: oral dose placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine Plus Lamotrigine</title>
          <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Lamotrigine: lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine</description>
        </group>
        <group group_id="B2">
          <title>Ketamine Plus Placebo</title>
          <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Placebo: oral dose placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Due to the small sample size in each arm, we did not analyze the ages separately and baseline measures were not provided to protect confidentiality of participants. We provided date for the analysis of age for the total number of participants.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" spread="NA">data was not analyzed due to the small sample size</measurement>
                    <measurement group_id="B2" value="NA" spread="NA">data was not analyzed due to the small sample size</measurement>
                    <measurement group_id="B3" value="40" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-Ketamine Rs-fMRI Data</title>
        <description>24 hours post infusion fMRI data</description>
        <time_frame>24 hours</time_frame>
        <population>Imaging data were not extracted to protect confidentiality of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Plus Lamotrigine</title>
            <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Lamotrigine: lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Plus Placebo</title>
            <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Placebo: oral dose placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Ketamine Rs-fMRI Data</title>
          <description>24 hours post infusion fMRI data</description>
          <population>Imaging data were not extracted to protect confidentiality of participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Global Brain Connectivity</title>
        <description>Participants will be randomized into one of two parallel groups—ketamine+lamotrigine or ketamine+placebo—and will complete pre- and post-ketamine rs-fMRI.
The hypothesis is that post-ketamine rs-fMRI data will demonstrate a pattern of increased global brain connectivity (GBC) in fronto-temporal cortex.
Insufficient number of participants for data collection.</description>
        <time_frame>24 hours</time_frame>
        <population>Insufficient number of participants for data collection</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Plus Lamotrigine</title>
            <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Lamotrigine: lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Plus Placebo</title>
            <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Placebo: oral dose placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Global Brain Connectivity</title>
          <description>Participants will be randomized into one of two parallel groups—ketamine+lamotrigine or ketamine+placebo—and will complete pre- and post-ketamine rs-fMRI.
The hypothesis is that post-ketamine rs-fMRI data will demonstrate a pattern of increased global brain connectivity (GBC) in fronto-temporal cortex.
Insufficient number of participants for data collection.</description>
          <population>Insufficient number of participants for data collection</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine Plus Lamotrigine</title>
          <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Lamotrigine: lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine</description>
        </group>
        <group group_id="E2">
          <title>Ketamine Plus Placebo</title>
          <description>Ketamine: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Placebo: oral dose placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chadi Abdallah</name_or_title>
      <organization>Yale School of Medicine</organization>
      <phone>347-987-0717</phone>
      <email>chadi.abdallah@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

